SIMPLIFY HEALTH CARE ETF(PINK)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

PINK SIMPLIFY HEALTH CARE ETF

交易中 11-03 10:04:16 EST

40.12

+0.04

+0.10%

最高40.12	最低40.12	成交量457.00
今开40.12	昨收40.08	日振幅0.00%
总市值3.31亿	流通市值3.31亿	总股本825.00万
成交额1.84万	换手率0.01%	流通股本825.00万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"PINK","market":"US","secType":"STK","nameCN":"SIMPLIFY HEALTH CARE ETF","latestPrice":40.12,"timestamp":1793718120036,"preClose":40.08,"halted":0,"volume":457,"delay":0,"changeRate":0.0009980039920159467,"floatShares":8250001,"shares":8250001,"eps":0,"marketStatus":"交易中","change":0.04,"latestTime":"11-03 10:04:16 EST","open":40.12,"high":40.12,"low":40.12,"amount":18410.70657,"amplitude":0,"askPrice":40.77,"askSize":100,"bidPrice":40.3,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1793739600000},"marketStatusCode":2,"adr":0,"exchange":"ARCA","adjPreClose":40.08,"sharesOutstanding":7975001,"nav":40.049,"aum":344535759.1,"dividendRate":0.007493,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":40.08,"preClose":40.08,"latestTime":"07:37 EST","volume":1,"amount":40.08,"timestamp":1793709425416,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":40.08,"preClose":40.08,"latestTime":"19:30 EST","volume":12,"amount":480.96,"timestamp":1793665802933,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.057878,"impliedVol":0.0891,"impliedVolPercentile":0.4582},"requestUrl":"/m/hq/s/PINK","defaultTab":"news","newsList":[{"id":"2679264004","title":"AI交易之外的增长王牌！礼来(LLY.US)减肥药放量与新品接力，摩根大通上调目标价至1650美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2679264004","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679264004?lang=zh_cn&edition=full","pubTime":"2026-10-30 15:26","pubTimestamp":1793345179,"startTime":"0","endTime":"0","summary":"截至10月29日美股收盘，礼来逆势大涨6.63%，而纳斯达克100指数和费城半导体指数分别下跌1.38%和1.42%。礼来营收和核心减肥药销售均表现强劲，进一步验证了其代谢业务的增长势头，也为摩根大通上修长期盈利预测提供了业绩依据。除了代谢业务，礼来的非肥胖治疗领域也已出现增长基础。该行预计，礼来整体肠促胰素业务收入将由2026年的650亿美元增长至2027年的820亿美元，2030年接近1100亿美元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1515969.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IYH","THNR","AGIX","XLVI","UUP","NBDS","PJP","CURE","MEDI","ARTY","AIPO","FXH","TRUH","CHAT","PINK","RSPH","UDN","QTOC","FHLC","NVOC","PGF","VTHR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679262815","title":"AI交易之外的增长王牌！礼来(LLY.US)减肥药放量与新品接力，摩根大通上调目标价至1650美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2679262815","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679262815?lang=zh_cn&edition=full","pubTime":"2026-10-30 15:26","pubTimestamp":1793345179,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["XLVI","FHLC","AGIX","PJP","QTOC","TRUH","MEDI","RSPH","CHAT","BK4582","FXH","THNR","PGF","AIPO","PINK","IYH","NVOH","NVOC","ARTY","UDN","NVOX","CURE","UUP","VTHR","NBDS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679283984","title":"礼来股价创历史新高，市值达1.15万亿美元，机构看好减肥药销售增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2679283984","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679283984?lang=zh_cn&edition=full","pubTime":"2026-10-29 21:37","pubTimestamp":1793281046,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MEDI","FXH","RSPH","TRUH","PINK","THNR","XLVI","IYH","CURE","NVOC","NVOH","FHLC","NVOX","PJP","NBDS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678461201","title":"美国法官拒绝禁令，诺和诺德(NVO.US)阻击礼来(LLY.US)减肥药广告首战失利","url":"https://stock-news.laohu8.com/highlight/detail?id=2678461201","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678461201?lang=zh_cn&edition=full","pubTime":"2026-10-27 10:19","pubTimestamp":1793067599,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MEDI","NVOC","FHLC","IYH","XLVI","TRUH","PINK","CURE","FXH","NBDS","PJP","RSPH","NVOH","THNR","NVOX","BGIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678146127","title":"美国法官拒绝禁令，诺和诺德(NVO.US)阻击礼来(LLY.US)减肥药广告首战失利","url":"https://stock-news.laohu8.com/highlight/detail?id=2678146127","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678146127?lang=zh_cn&edition=full","pubTime":"2026-10-27 10:19","pubTimestamp":1793067599,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周一，美国一名法官驳回了诺和诺德要求禁止礼来继续投放减肥药广告的请求。该法官表示，金钱赔偿可以弥补诺和诺德在未获禁令情况下可能遭受的任何“非轻微损害”。法院文件显示，诺和诺德报告其减肥药物和Ozempic在2025年的合计销售额约为320亿美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1513061.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["RSPH","PINK","XLVI","FHLC","CURE","IYH","NBDS","NVOX","PJP","THNR","TRUH","FXH","NVOH","BGIA","NVOC","MEDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677948476","title":"喜力公司的一份演示文件显示，该公司已敦促英国酒吧和餐饮场所适应减肥药使用热潮，否则可能面临顾客流失和收入下滑的风险。这是","url":"https://stock-news.laohu8.com/highlight/detail?id=2677948476","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677948476?lang=zh_cn&edition=full","pubTime":"2026-10-23 14:11","pubTimestamp":1792735913,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IYH","NVOC","PINK","XLVI","RSPH","TRUH","NBDS","NVOH","PJP","FHLC","CURE","FXH","NVOX","THNR","MEDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677960932","title":"欧莱雅首席执行官：减肥药使用增加将提振护肤品业务。","url":"https://stock-news.laohu8.com/highlight/detail?id=2677960932","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677960932?lang=zh_cn&edition=full","pubTime":"2026-10-23 01:05","pubTimestamp":1792688741,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["FHLC","NVOC","PINK","TRUH","LRLCY","FXH","MEDI","BK4183","IYH","CURE","RSPH","THNR","XLVI","NVOX","NBDS","PJP","NVOH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677170896","title":"美股异动丨诺和诺德新一代减肥药进展积极，减肥药概念股走强","url":"https://stock-news.laohu8.com/highlight/detail?id=2677170896","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677170896?lang=zh_cn&edition=full","pubTime":"2026-10-21 07:55","pubTimestamp":1792540520,"startTime":"0","endTime":"0","summary":"减肥药概念股走强，礼来、Viking Therapeutics涨近5%，罗氏涨超3%，安进、诺和诺德涨超2%。\n\n　　消息面上，诺和诺德新一代减肥药传来新进展，一项基于后期临床试验的数据分析显示，其新一代减肥药CagriSema在肥胖或超重成年女性中实现了平均25%的体重降幅。公司指出，仍需开展进一步研究，以验证数据分析的结果。(格隆汇)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20261021/32403095.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["PJP","NBDS","MEDI","NVOC","XLVI","FXH","BGIA","CURE","NVOX","NVOH","THNR","TRUH","RSPH","FHLC","PINK","IYH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676692391","title":"美股异动丨诺和诺德新一代减肥药进展积极，减肥药概念股走强","url":"https://stock-news.laohu8.com/highlight/detail?id=2676692391","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676692391?lang=zh_cn&edition=full","pubTime":"2026-10-20 22:56","pubTimestamp":1792508199,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["MEDI","NVOH","NBDS","PJP","XLVI","IYH","PINK","RSPH","TRUH","NVOX","NVOC","CURE","THNR","FXH","FHLC","BGIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676469122","title":"有望超越司美格鲁肽 诺和诺德新减肥药实现成年女性受试者平均减重25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2676469122","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676469122?lang=zh_cn&edition=full","pubTime":"2026-10-20 22:12","pubTimestamp":1792505520,"startTime":"0","endTime":"0","summary":"诺和诺德周二公布，在一项三期临床试验后的新增分析中，其新一代减重药CagriSema在成年女性受试者身上实现平均减重25%。司美格鲁肽是爆款减重针Wegovy、降糖药Ozempic的有效成分。CagriSema由司美格鲁肽与靶向胰淀素通路的cagrilintide复合而成，预计将于明年初上市。该分析纳入约2300名肥胖或超重女性：持续用药68周后，CagriSema组平均减重25%，安慰剂组仅3%。这项研究最初数据显示：68周时成人平均减重22.7%，安慰剂组2.3%。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-10-20/doc-inivwuic7765455.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IYH","TRUH","NVOC","FHLC","CURE","MEDI","RSPH","XLVI","FXH","NBDS","PINK","PJP","THNR","NVOX","NVOH","BGIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676469691","title":"诺和诺德新减肥药试验成果：成年女性受试者实现平均减重25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2676469691","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676469691?lang=zh_cn&edition=full","pubTime":"2026-10-20 22:10","pubTimestamp":1792505429,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["CURE","MEDI","PINK","PJP","TRUH","NVOH","NVOC","NVOX","THNR","BGIA","NBDS","FHLC","XLVI","IYH","RSPH","FXH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676913626","title":"诺和诺德表示，其新一代减肥药CagriSema在肥胖或超重成年女性中实现了平均25%的体重降幅。","url":"https://stock-news.laohu8.com/highlight/detail?id=2676913626","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676913626?lang=zh_cn&edition=full","pubTime":"2026-10-20 21:59","pubTimestamp":1792504777,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["MEDI","NBDS","NVOC","FXH","PINK","TRUH","NVOH","BGIA","RSPH","CURE","XLVI","FHLC","THNR","PJP","NVOX","IYH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674571328","title":"国产减肥药公布积极研究数据，GLP-1药物进入长效竞争？","url":"https://stock-news.laohu8.com/highlight/detail?id=2674571328","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674571328?lang=zh_cn&edition=full","pubTime":"2026-10-09 21:41","pubTimestamp":1791553260,"startTime":"0","endTime":"0","summary":"10月9日，广东众生药业股份有限公司（众生药业，002317）10%涨停。消息面上，10月8日晚间，众生药业发布公告称，控股子公司广东众生睿创生物科技有限公司（简称“众生睿创”）自主研发的一类创新多肽药物RAY1225注射液在超重或肥胖参与者的安全性和有效性的多中心、随机、双盲、安慰剂对照的三期临床试验，于近日获得顶线分析数据。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610093891510724.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610093891510724.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["MEDI","THNR","FXH","NVOX","PJP","FHLC","NVOH","JDOC","TRUH","PINK","XLVI","CURE","RSPH","NBDS","NVOC","IYH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673891024","title":"减肥药还能抗衰老？第一款大众抗衰药可能正在路上","url":"https://stock-news.laohu8.com/highlight/detail?id=2673891024","media":"麻省理工科技评论","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673891024?lang=zh_cn&edition=full","pubTime":"2026-10-08 15:36","pubTimestamp":1791444960,"startTime":"0","endTime":"0","summary":"热门减肥药可能不只可以帮助人们减掉体重，还可能让岁月的痕迹一同消退。他被认为是“衰老时钟”的发明者之一。它们能够改善肾功能、降低血压，甚至显著降低总体死亡风险。诺和诺德发现，随着时间推移，这些药物能够让多种衰老时钟显示出衰老减缓的迹象。多位与会者提醒，GLP-1 类药物确实存在副作用，其中包括肌肉流失。与此同时，该项目还希望帮助建立针对抗衰老药物的监管路径，并围绕长寿领域“建立一个新的治疗产业”。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://tech.ifeng.com/c/8x3ZZsOsIiW","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fenghuang_stock","symbols":["MEDI","THNR","FXH","NVOX","PJP","FHLC","NVOH","TRUH","PINK","XLVI","CURE","RSPH","NBDS","NVOC","IYH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673808042","title":"Zealand Pharma与罗氏在研减肥药中期临床试验帮助患者减重高达9.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2673808042","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673808042?lang=zh_cn&edition=full","pubTime":"2026-10-08 10:37","pubTimestamp":1791427037,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["RSPH","IBBQ","MDTX","PJP","NVOH","NVOC","IBBJ","FXH","TRUH","MEDI","XLVI","PINK","NBDS","BMED","IYH","FHLC","THNR","PSYK","CURE","NVOX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671772271","title":"2026诺奖前瞻：GLP-1减肥药背后的科学家成热门人选","url":"https://stock-news.laohu8.com/highlight/detail?id=2671772271","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671772271?lang=zh_cn&edition=full","pubTime":"2026-09-30 16:07","pubTimestamp":1790755679,"startTime":"0","endTime":"0","summary":"来源：环球市场播报2026年诺奖得主将于10月5日至12日陆续公布。值得注意的是，此次的诺奖预测中，有五位被提及的生理学或医学奖潜在人选均与GLP-1研究及相关药物开发密切相关。Lotte Bjerre Knudsen是药物科学家，在诺和诺德任职期间，挖掘了GLP-1在糖尿病和体重管理领域的潜力，她是2025年生命科学突破奖得主。哈佛大学生物化学家David Liu，为2025年生命科学突破奖得主。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2026/09/30160758594138.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["NVOC","RSPH","ELIL","NBDS","ELIS","IYH","NVOH","PJP","TRUH","XLVI","OZEM","FXH","PINK","FHLC","LLII","LLYX","NVOX","JDOC","MEDI","CURE","THNR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671827131","title":"2026诺奖前瞻：GLP-1减肥药背后的科学家成热门人选","url":"https://stock-news.laohu8.com/highlight/detail?id=2671827131","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671827131?lang=zh_cn&edition=full","pubTime":"2026-09-30 15:56","pubTimestamp":1790754987,"startTime":"0","endTime":"0","summary":"2026年诺奖得主将于10月5日至12日陆续公布。为了解热门候选名单，《The Scientist》刊发了科学家们对2026年诺贝尔生理学或医学奖、物理学奖、化学奖得主的预测。值得注意的是，此次的诺奖预测中，有五位被提及的医学奖潜在人选均与GLP-1研究及相关药物开发密切相关。Lotte Bjerre Knudsen是药物科学家，在诺和诺德任职期间，挖掘了GLP-1在糖尿病和体重管理领域的潜力，她是2025年生命科学突破奖得主。哈佛大学生物化学家David Liu，为2025年生命科学突破奖得主。","market":"us","thumbnail":"https://n.sinaimg.cn/finance/transform/79/w550h329/20260930/d305-020e775d38bcdf7e36c23a699d390096.png","type":0,"news_type":0,"thumbnails":["https://n.sinaimg.cn/finance/transform/79/w550h329/20260930/d305-020e775d38bcdf7e36c23a699d390096.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-09-30/doc-initqzmc5708551.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina_us","symbols":["XLVI","FHLC","PJP","TRUH","MEDI","RSPH","ELIL","FXH","THNR","PINK","IYH","OZEM","LLYX","NVOH","NVOC","JDOC","LLII","NVOX","CURE","ELIS","NBDS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671279010","title":"2026诺奖前瞻：GLP-1减肥药背后的科学家成热门人选","url":"https://stock-news.laohu8.com/highlight/detail?id=2671279010","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671279010?lang=zh_cn&edition=full","pubTime":"2026-09-30 15:51","pubTimestamp":1790754672,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["TRUH","FHLC","LLII","LLYX","PINK","IYH","NVOC","RSPH","JDOC","NVOX","XLVI","ELIS","FXH","MEDI","CURE","NVOH","ELIL","NBDS","PJP","OZEM","THNR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671524876","title":"交易额最高可达26亿美元！诺和诺德买下恒瑞“每周一次口服”减肥药 两大外资药企巨头周制剂布局均靠“外援”","url":"https://stock-news.laohu8.com/highlight/detail?id=2671524876","media":"每日经济新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671524876?lang=zh_cn&edition=full","pubTime":"2026-09-29 22:37","pubTimestamp":1790692650,"startTime":"0","endTime":"0","summary":"9月29日，恒瑞医药（SH600276，股价45.62元，总市值3028亿元）公告称，公司将潜在每周一次口服给药的胰高血糖素样肽-1（GLP-1）和抑胃肽（GIP）双受体激动剂HRS-1596有偿许可给诺和诺德。诺和诺德将获得HRS-1596在大中华地区以外的全球范围内开发、生产和商业化的独家权利。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609293886793117.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609293886793117.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IYH","PJP","BGIA","NBDS","NVOC","CURE","NVOX","FXH","RSPH","THNR","NVOH","PINK","XLVI","FHLC","MEDI","TRUH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671216897","title":"礼来：减肥药Zepbound 10毫克和15毫克剂型因不良反应停药的比例与Wegovy高剂量组相当。","url":"https://stock-news.laohu8.com/highlight/detail?id=2671216897","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671216897?lang=zh_cn&edition=full","pubTime":"2026-09-29 19:02","pubTimestamp":1790679728,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["RSPH","MEDI","FHLC","NVOC","PINK","TRUH","THNR","PJP","CURE","NVOX","FXH","NBDS","XLVI","IYH","NVOH"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.011},{"period":"1month","weight":0.0511},{"period":"3month","weight":0.0142},{"period":"6month","weight":0.1322},{"period":"1year","weight":0.2007},{"period":"ytd","weight":0.0951}],"compareEarnings":[{"period":"1week","weight":-0.0173},{"period":"1month","weight":-0.0228},{"period":"3month","weight":-0.0249},{"period":"6month","weight":0.0249},{"period":"1year","weight":0.1027},{"period":"ytd","weight":0.1029}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.012643},{"month":2,"riseRate":0.6,"avgChangeRate":0.005136},{"month":3,"riseRate":0.6,"avgChangeRate":-0.001509},{"month":4,"riseRate":0.6,"avgChangeRate":-0.008129},{"month":5,"riseRate":0.6,"avgChangeRate":0.008295},{"month":6,"riseRate":0.8,"avgChangeRate":0.032925},{"month":7,"riseRate":0.6,"avgChangeRate":0.011634},{"month":8,"riseRate":0.6,"avgChangeRate":0.002039},{"month":9,"riseRate":0.2,"avgChangeRate":-0.01329},{"month":10,"riseRate":0.6,"avgChangeRate":0.025267},{"month":11,"riseRate":0.666667,"avgChangeRate":0.032803},{"month":12,"riseRate":0.4,"avgChangeRate":0.008788}],"exchange":"ARCA","name":"SIMPLIFY HEALTH CARE ETF","nameEN":"SIMPLIFY HEALTH CARE ETF"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.1","shortVersion":"4.52.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"SIMPLIFY HEALTH CARE ETF(PINK)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供SIMPLIFY HEALTH CARE ETF(PINK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"SIMPLIFY HEALTH CARE ETF,PINK,SIMPLIFY HEALTH CARE ETF股票,SIMPLIFY HEALTH CARE ETF股票老虎,SIMPLIFY HEALTH CARE ETF股票老虎国际,SIMPLIFY HEALTH CARE ETF行情,SIMPLIFY HEALTH CARE ETF股票行情,SIMPLIFY HEALTH CARE ETF股价,SIMPLIFY HEALTH CARE ETF股市,SIMPLIFY HEALTH CARE ETF股票价格,SIMPLIFY HEALTH CARE ETF股票交易,SIMPLIFY HEALTH CARE ETF股票购买,SIMPLIFY HEALTH CARE ETF股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"SIMPLIFY HEALTH CARE ETF(PINK)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供SIMPLIFY HEALTH CARE ETF(PINK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}